Bull Harbor Capital LLC Purchases Shares of 23,691 Merck & Co., Inc. $MRK

Bull Harbor Capital LLC acquired a new stake in Merck & Co., Inc. (NYSE:MRK) in the 1st quarter, HoldingsChannel reports. The fund acquired 23,691 shares of the company’s stock, valued at approximately $2,850,000. Merck & Co., Inc. makes up about 0.8% of Bull Harbor Capital LLC’s investment portfolio, making the stock its 16th biggest holding.

Several other hedge funds and other institutional investors have also made changes to their positions in MRK. Kingdom Financial Group LLC. bought a new stake in Merck & Co., Inc. during the fourth quarter worth $25,000. Prosperity Bancshares Inc acquired a new position in shares of Merck & Co., Inc. during the 4th quarter worth about $26,000. Abound Financial LLC acquired a new position in shares of Merck & Co., Inc. during the 4th quarter worth about $26,000. IFC & Insurance Marketing Inc. bought a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at about $31,000. Finally, High Note Wealth LLC raised its holdings in shares of Merck & Co., Inc. by 58.9% in the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after purchasing an additional 109 shares during the period. 76.07% of the stock is owned by institutional investors.

Merck & Co., Inc. Trading Down 1.0%

Shares of MRK stock opened at $130.45 on Thursday. Merck & Co., Inc. has a 12-month low of $77.53 and a 12-month high of $135.05. The company has a market capitalization of $322.18 billion, a PE ratio of 36.75, a price-to-earnings-growth ratio of 5.23 and a beta of 0.19. The firm has a 50 day moving average price of $122.73 and a two-hundred day moving average price of $118.24. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, beating the consensus estimate of ($1.47) by $0.19. The company had revenue of $16.29 billion for the quarter, compared to the consensus estimate of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The firm’s revenue for the quarter was up 4.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.22 earnings per share. As a group, analysts predict that Merck & Co., Inc. will post 2.74 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be given a dividend of $0.85 per share. The ex-dividend date is Tuesday, September 15th. This represents a $3.40 annualized dividend and a yield of 2.6%. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 95.77%.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Barclays raised its price target to $150 from $140 and maintained an “overweight” rating, implying roughly 15% upside from the referenced price. The increase reflects continued confidence in Merck’s outlook. Barclays raises Merck price target
• Positive Sentiment: KEYTRUDA met its primary progression-free-survival endpoint in a Phase 3 trial for advanced or recurrent endometrial cancer, outperforming platinum-based chemotherapy. Merck said the result could support future regulatory filings and strengthen its oncology pipeline. Merck KEYTRUDA endometrial cancer trial
• Positive Sentiment: Merck announced its fourth-quarter 2026 dividend, reinforcing the stock’s appeal to income-oriented investors and signaling continued capital-return support. The provided announcement did not include the dividend amount or payment details. Merck fourth-quarter dividend announcement
• Neutral Sentiment: Wells Fargo reiterated its Buy rating, while broader brokerage coverage places Merck at a “Moderate Buy” consensus, indicating generally favorable but not universally bullish sentiment. Wells Fargo maintains Merck Buy rating
• Negative Sentiment: Analysts expect Merck’s second-quarter earnings to decline, and a Zacks preview says the company lacks the typical signals associated with a likely earnings beat. This raises near-term execution risk ahead of the earnings report. Merck second-quarter earnings preview

Analyst Upgrades and Downgrades

MRK has been the subject of a number of research analyst reports. Citigroup initiated coverage on Merck & Co., Inc. in a report on Wednesday, May 6th. They set a “neutral” rating and a $125.00 price target for the company. BMO Capital Markets increased their price target on Merck & Co., Inc. from $135.00 to $142.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Wells Fargo & Company raised their price target on Merck & Co., Inc. from $145.00 to $150.00 and gave the company an “overweight” rating in a report on Wednesday, July 8th. Weiss Ratings cut shares of Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a research report on Friday, May 15th. Finally, Scotiabank upped their price objective on shares of Merck & Co., Inc. from $136.00 to $155.00 and gave the company a “sector outperform” rating in a report on Tuesday, June 30th. Thirteen investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $134.50.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.